查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1678487

全球眼科藥物市場：市場規模、佔有率、趨勢分析（按藥物類別、疾病、給藥方法、給藥途徑、產品類型、藥物類型和地區）、細分市場預測（2025-2030 年）

Ophthalmic Drugs Market Size, Share & Trends Analysis Report By Drug Class (Steroidal drugs, Anti-VEGF Agents), By Disease, By Dosage Form, By Route of Administration, By Product Type, By Drug Type, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

眼科藥品市場的成長與趨勢：

根據Grand View Research, Inc.的最新報告，到2030年全球眼科藥物市場規模預計將達到620.8億美元，2025年至2030年期間的複合年成長率為8.5%。

人們對眼部疾病認知的提高和對眼科藥物的需求激增是推動市場成長的因素。此外，老齡化黃斑部病變、白內障、乾眼症、糖尿病視網膜病變和青光眼等眼科疾病的盛行率不斷上升，預計將推動對眼科藥物的需求。

根據 BrightFocus 基金會估計，2021 年將有超過 300 萬美國患有青光眼，其中超過 270 萬名患者患有最常見的青光眼類型：開放性青光眼。此外，美國有 330 萬人患有失明或視力低下。青光眼和失明的主要危險因子包括年齡較大、家族病史、角膜較薄和眼壓高。這為眼科用藥創造了廣泛的人口基礎，確保了良好的成長。

此外，眼科護理和藥物輸送公司正在獲得資金支持，以促進開發新藥技術進步的研究和開發，這可能會推動市場成長。例如，2020 年 6 月，Re-Vana Therapeutics 從 Qubis、ExSight Ventures, LLC、Clarendon Fund Managers、Visionary Ventures 和 Techstart Ventures LLP 籌集了 325 萬美元的 A 輪前融資。這筆資金籌措預計將加速 Li-Vana Therapeutics 的 EyeLief 和 OcuLief生物分解性技術的開發，這些技術可用於遞送小分子和生技藥品。

此外，老年人口的增加是眼科藥物市場成長的主要驅動力。根據美國安全眼睛組織的數據，導致眼疾最常見的風險因素是年齡較大、家族病史、糖尿病和高血壓。例如，根據《2021年美國健康排名》老年人報告估計，美國65歲及以上的成年人口超過5,400萬，佔總人口的16.5%。根據黃斑部病變調查，AMD 是導致 60 歲以上美國失明的主要原因。

眼科產品的持續監管核准可能會支持市場成長。例如，參天製藥株式會社於 2022 年 6 月宣布，已獲得日本治療乾眼症的藥物 Diquas LX 眼藥水的生產和銷售核准。這種眼藥水是一種改良配方，可減少給藥頻率並提高患者的依從性。

眼科藥品市場：概覽

  • 由於需求增加且副作用減少，抗 VEGF 藥物在 2024 年佔據最大佔有率。
  • 由於老齡化黃斑部病變和糖尿病視網膜病變的盛行率不斷上升，視網膜病變在 2024 年佔據了最大的市場佔有率。
  • 局部給藥途徑由於能夠將藥物輸送到目標部位和易於使用等優勢，在 2024 年佔據了市場主導地位。
  • 由於眼藥水需求不斷成長、患者依從性高和非處方產品易於獲得，預計眼藥水市場將在 2024 年佔據最大佔有率。
  • 由於醫療保健基礎設施的進步、眼科產品需求的增加以及患者人數的龐大，預計亞太地區將在預測期內呈現最快的成長。

目錄

第1章 分析方法及範圍

第 2 章執行摘要

第3章眼科藥物市場：促進因素、趨勢與範圍

  • 市場聯動展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制分析
  • 眼科藥品市場：分析工具
    • 產業分析：波特五力分析
    • PESTEL 分析

第 4 章 眼科藥物市場：按藥物類別的估計和趨勢分析

  • 細分儀表板
  • 眼科藥物市場：依藥物類別變化分析
  • 眼科藥品市場：按藥品類別分類的市場規模預測和趨勢分析（2018-2030 年）
  • 抗過敏
  • 抗VEGF藥物
  • 消炎（藥
    • 非類固醇藥物
    • 類固醇
  • 青光眼預防
  • 基因和細胞治療
  • 其他

第 5 章眼科藥物市場：按疾病的估計和趨勢分析

  • 細分儀表板
  • 眼科藥品市場：疾病趨勢分析
  • 眼科藥品市場：按疾病分類的市場規模預測和趨勢分析（2018-2030 年）
  • 眼睛乾澀
  • 過敏
  • 青光眼
  • 感染
  • 視網膜疾病
    • 按給藥方式
    • 按類型
  • 葡萄膜炎
  • 其他

第6章 眼藥水市場：依給藥途徑的估計與趨勢分析

  • 細分儀表板
  • 眼科用藥市場：給藥途徑變化分析
  • 眼科藥品市場：按給藥途徑分類的市場規模預測和趨勢分析（2018-2030 年）
  • 局部的
  • 局部眼
  • 局部的

第7章眼科藥物市場：按管理方式的估計和趨勢分析

  • 細分儀表板
  • 眼科用藥市場：給藥方式變化分析
  • 眼科藥品市場：按管理方式分類的市場規模預測和趨勢分析（2018-2030 年）
  • 凝膠
  • 眼用溶液和混懸液
  • 膠囊和錠劑
  • 眼藥水
  • 軟膏

第 8 章眼科藥物市場：按產品類型的估計和趨勢分析

  • 細分儀表板
  • 眼科藥品市場：依產品類型進行的波動分析
  • 眼科藥品市場：按產品類型分類的市場規模預測和趨勢分析（2018-2030 年）
  • 場外交易（OTC）
  • 處方藥

第 9 章眼科藥物市場：按藥物類型的估計和趨勢分析

  • 細分儀表板
  • 眼科藥品市場：藥品類型波動分析
  • 眼科藥品市場：按藥品類型分類的市場規模預測和趨勢分析（2018-2030 年）
  • 品牌藥物
  • 學名藥

第 10 章眼科藥物市場：按地區分類的估計和趨勢分析

  • 各地區市場佔有率分析（2023 年及 2030 年）
  • 市場儀表板：按地區
  • 全球市場概況：按地區
  • 市場規模預測及趨勢分析（2018-2030年）
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麥
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第11章 競爭格局

  • 主要市場參與企業的近期趨勢和影響分析
  • 公司/競爭對手分類
  • 供應商概況
    • 主要經銷商及通路夥伴名單
    • Key customers
    • Key company market share analysis, 2023
    • Alcon
    • Novartis AG
    • Bausch Health Companies, Inc.
    • Merck &Co., Inc.
    • Regeneron Pharmaceuticals, Inc.
    • Coherus BioSciences, Inc.
    • AbbVie, Inc.（Allergan）
    • Pfizer, Inc.
    • Bayer AG
    • Santen Pharmaceutical Co., Ltd.
    • Roche（Genentech, Inc.）
    • Nicox
Product Code: GVR-2-68038-010-1

Ophthalmic Drugs Market Growth & Trends:

The global ophthalmic drugs market size is expected to reach USD 62.08 billion by 2030, garnering a CAGR of 8.5% from 2025 to 2030, according to a new report by Grand View Research, Inc. The rising awareness about ophthalmic disorders and the surge in demand for ophthalmic drugs are the factors propelling the market growth. Moreover, an increase in the prevalence of eye diseases such as age-related macular degeneration, cataract, dry eye, diabetic retinopathy, glaucoma, and others are anticipated to boost the demand for ophthalmic drugs.

According to BrightFocus Foundation in 2021, it is estimated that over 3 million Americans are living with glaucoma, and, among them over 2.7 million patients were affected by the most common type of glaucoma i.e. open-angle glaucoma. Moreover, 3.3 million people are affected by blindness and low vision in the U.S. Some of the major risk factors for glaucoma and blindness are, higher age, family history, thin cornea, and high eye pressure. This creates a wide population base for ophthalmic drugs, thereby, ensuring lucrative growth.

Furthermore, ocular therapeutic and drug delivery companies are receiving funding to expedite R&D for advancements in technologies to develop novel drugs, which is likely to fuel market growth. For instance, in June 2020, Re-Vana Therapeutics received USD 3.25 million in pre-series A funding from Qubis, ExSight Ventures, LLC, Clarendon Fund Managers, Visionary Ventures, and Techstart Ventures LLP. The funding is expected to boost the development of Re-Vana Therapeutics' EyeLief & OcuLief biodegradable technologies that can be used for a small molecule as well as biologics delivery.

Moreover, the rising geriatric population is the key driver for the ophthalmic drugs market growth. According to Safe Eyes America, the most common risk factors for ophthalmic diseases are high age, family history, diabetes, and high blood pressure. For instance, as per AMERICA's HEALTH RANKINGS senior report 2021 it was estimated that more than 54 million adults of age more than 65 live in the U.S., and that population accounted for 16.5% of the total population. According to Macular Degeneration Research AMD is the leading reason for blindness in U.S. people over the age of 60.

Ongoing regulatory approvals for ophthalmic products are likely to support market growth. For instance, in June 2022 Santen Pharmaceutical Co., Ltd announced that it has got marketing and manufacturing approval for the dry eye disease treatment DIQUAS LX ophthalmic solution in Japan. This solution is the improved formulation that has reduced dosing frequency and improved patient compliance.

Ophthalmic Drugs Market Report Highlights:

  • Anti-VEGF agents segment held the largest share in 2024 owing to their rising demand and lesser adverse effects
  • Retinal disorders held the largest market share in 2024 owing to the rising prevalence of age-related macular degeneration and diabetic retinopathy
  • The topical route of administration dominated the market in 2024 owing to factors such as the benefits of the topical route as it delivers the drug to the targeted site and ease of use
  • The eye drops segment is expected to hold the largest share in 2024 owing to rising demand for eye drops, high patient compliance, and availability of OTC products
  • Asia Pacific is expected to exhibit the fastest growth over the forecast period due to advancements in healthcare infrastructure, increasing demand for eye products, and a large patient pool

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Drug class
    • 1.2.2. Disease
    • 1.2.3. Route of administration
    • 1.2.4. Dosage type
    • 1.2.5. Product type
    • 1.2.6. Drug type
    • 1.2.7. Regional scope
    • 1.2.8. Estimates and forecasts timeline.
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Drug class outlook
    • 2.2.2. Disease outlook
    • 2.2.3. Route of administration outlook
    • 2.2.4. Dosage type outlook
    • 2.2.5. Product type outlook
    • 2.2.6. Drug type outlook
    • 2.2.7. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Ophthalmic Drugs Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook.
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Increasing diseases prevalence
      • 3.2.1.2. String development pipeline
      • 3.2.1.3. Advancements in drug delivery
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Patent expiry of blockbuster drugs
  • 3.3. Ophthalmic Drugs Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
    • 3.3.2. PESTEL Analysis

Chapter 4. Ophthalmic Drugs Market: Drug Class Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Ophthalmic Drugs Market: Drug Class Movement Analysis
  • 4.3. Ophthalmic Drugs Market Size & Trend Analysis, by Drug Class, 2018 to 2030 (USD Million)
  • 4.4. Anti-Allergy
    • 4.4.1. Anti-Allergy market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.5. Anti-VEGF agents
    • 4.5.1. Anti-VEGF agents market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.6. Anti-inflammatory
    • 4.6.1. Anti-inflammatory market revenue estimates and forecasts, 2018 - 2030 (USD Million)
    • 4.6.2. Non-steroidal Drugs
      • 4.6.2.1. Non-steroidal Drugs market revenue estimates and forecasts, 2018 - 2030 (USD Million)
    • 4.6.3. Steroids
      • 4.6.3.1. Steroids market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.7. Anti-glaucoma
    • 4.7.1. Anti-glaucoma market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.8. Gene & Cell Therapy
    • 4.8.1. Gene & Cell Therapy market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.9. Others
    • 4.9.1. Others market revenue estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 5. Ophthalmic Drugs Market: Disease Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Ophthalmic Drugs Market: Disease Movement Analysis
  • 5.3. Ophthalmic Drugs Market Size & Trend Analysis, by Disease, 2018 to 2030 (USD Million)
  • 5.4. Dry eye
    • 5.4.1. Dry eye market revenue estimates and forecasts, 2018 - 2030 (USD Million)
      • 5.4.1.1. Gels
        • 5.4.1.1.1. Gels market revenue estimates and forecasts, 2018 - 2030 (USD Million)
      • 5.4.1.2. Eye solutions & suspensions
        • 5.4.1.2.1. Eye solutions & suspensions market revenue estimates and forecasts, 2018 - 2030 (USD Million)
      • 5.4.1.3. Capsules & tablets
        • 5.4.1.3.1. Capsules & tablets market revenue estimates and forecasts, 2018 - 2030 (USD Million)
      • 5.4.1.4. Eye drops
        • 5.4.1.4.1. Eye drops market revenue estimates and forecasts, 2018 - 2030 (USD Million)
      • 5.4.1.5. Ointments
        • 5.4.1.5.1. Ointments market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.5. Allergies
    • 5.5.1. Allergies market revenue estimates and forecasts, 2018 - 2030 (USD Million)
      • 5.5.1.1. Gels
        • 5.5.1.1.1. Gels market revenue estimates and forecasts, 2018 - 2030 (USD Million)
      • 5.5.1.2. Eye solutions & suspensions
        • 5.5.1.2.1. Eye solutions & suspensions market revenue estimates and forecasts, 2018 - 2030 (USD Million)
      • 5.5.1.3. Capsules & tablets
        • 5.5.1.3.1. Capsules & tablets market revenue estimates and forecasts, 2018 - 2030 (USD Million)
      • 5.5.1.4. Eye drops
        • 5.5.1.4.1. Eye drops market revenue estimates and forecasts, 2018 - 2030 (USD Million)
      • 5.5.1.5. Ointments
        • 5.5.1.5.1. Ointments market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.6. Glaucoma
    • 5.6.1. Glaucoma market revenue estimates and forecasts, 2018 - 2030 (USD Million)
      • 5.6.1.1. Gels
        • 5.6.1.1.1. Gels market revenue estimates and forecasts, 2018 - 2030 (USD Million)
      • 5.6.1.2. Eye solutions & suspensions
        • 5.6.1.2.1. Eye solutions & suspensions market revenue estimates and forecasts, 2018 - 2030 (USD Million)
      • 5.6.1.3. Capsules & tablets
        • 5.6.1.3.1. Capsules & tablets market revenue estimates and forecasts, 2018 - 2030 (USD Million)
      • 5.6.1.4. Eye drops
        • 5.6.1.4.1. Eye drops market revenue estimates and forecasts, 2018 - 2030 (USD Million)
      • 5.6.1.5. Ointments
        • 5.6.1.5.1. Ointments market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.7. Infection
    • 5.7.1. Infection market revenue estimates and forecasts, 2018 - 2030 (USD Million)
      • 5.7.1.1. Gels
        • 5.7.1.1.1. Gels market revenue estimates and forecasts, 2018 - 2030 (USD Million)
      • 5.7.1.2. Eye solutions & suspensions
        • 5.7.1.2.1. Eye solutions & suspensions market revenue estimates and forecasts, 2018 - 2030 (USD Million)
      • 5.7.1.3. Capsules & tablets
        • 5.7.1.3.1. Capsules & tablets market revenue estimates and forecasts, 2018 - 2030 (USD Million)
      • 5.7.1.4. Eye drops
        • 5.7.1.4.1. Eye drops market revenue estimates and forecasts, 2018 - 2030 (USD Million)
      • 5.7.1.5. Ointments
        • 5.7.1.5.1. Ointments market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.8. Retinal Disorders
    • 5.8.1. Retinal disorders market revenue estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.8.2. By Dosage Type
      • 5.8.2.1. Gels
        • 5.8.2.1.1. Gels market revenue estimates and forecasts, 2018 - 2030 (USD Million)
      • 5.8.2.2. Eye solutions & suspensions
        • 5.8.2.2.1. Eye solutions & suspensions market revenue estimates and forecasts, 2018 - 2030 (USD Million)
      • 5.8.2.3. Capsules & tablets
        • 5.8.2.3.1. Capsules & tablets market revenue estimates and forecasts, 2018 - 2030 (USD Million)
      • 5.8.2.4. Eye drops
        • 5.8.2.4.1. Eye drops market revenue estimates and forecasts, 2018 - 2030 (USD Million)
      • 5.8.2.5. Ointments
        • 5.8.2.5.1. Ointments market revenue estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.8.3. By Type
      • 5.8.3.1. Macular degeneration
        • 5.8.3.1.1. Macular degeneration market revenue estimates and forecasts, 2018 - 2030 (USD Million)
      • 5.8.3.2. Diabetic retinopathy
        • 5.8.3.2.1. Diabetic retinopathy market revenue estimates and forecasts, 2018 - 2030 (USD Million)
      • 5.8.3.3. Others
        • 5.8.3.3.1. Others market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.9. Uveitis
    • 5.9.1. Uveitis market revenue estimates and forecasts, 2018 - 2030 (USD Million)
      • 5.9.1.1. Gels
        • 5.9.1.1.1. Gels market revenue estimates and forecasts, 2018 - 2030 (USD Million)
      • 5.9.1.2. Eye solutions & suspensions
        • 5.9.1.2.1. Eye solutions & suspensions market revenue estimates and forecasts, 2018 - 2030 (USD Million)
      • 5.9.1.3. Capsules & tablets
        • 5.9.1.3.1. Capsules & tablets market revenue estimates and forecasts, 2018 - 2030 (USD Million)
      • 5.9.1.4. Eye drops
        • 5.9.1.4.1. Eye drops market revenue estimates and forecasts, 2018 - 2030 (USD Million)
      • 5.9.1.5. Ointments
        • 5.9.1.5.1. Ointments market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.10. Others
    • 5.10.1. Others market revenue estimates and forecasts, 2018 - 2030 (USD Million)
      • 5.10.1.1. Gels
        • 5.10.1.1.1. Gels market revenue estimates and forecasts, 2018 - 2030 (USD Million)
      • 5.10.1.2. Eye solutions & suspensions
        • 5.10.1.2.1. Eye solutions & suspensions market revenue estimates and forecasts, 2018 - 2030 (USD Million)
      • 5.10.1.3. Capsules & tablets
        • 5.10.1.3.1. Capsules & tablets market revenue estimates and forecasts, 2018 - 2030 (USD Million)
      • 5.10.1.4. Eye drops
        • 5.10.1.4.1. Eye drops market revenue estimates and forecasts, 2018 - 2030 (USD Million)
      • 5.10.1.5. Ointments
        • 5.10.1.5.1. Ointments market revenue estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 6. Ophthalmic Drugs Market: Route of Administration Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Ophthalmic Drugs Market: Route of Administration Movement Analysis
  • 6.3. Ophthalmic Drugs Market Size & Trend Analysis, by Route of Administration, 2018 to 2030 (USD Million)
  • 6.4. Topical
    • 6.4.1. Topical market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.5. Local Ocular
    • 6.5.1. Local ocular market revenue estimates and forecasts, 2018 - 2030 (USD Million)
      • 6.5.1.1. Subconjunctival
        • 6.5.1.1.1. Subconjunctival market revenue estimates and forecasts, 2018 - 2030 (USD Million)
      • 6.5.1.2. Intravitreal
        • 6.5.1.2.1. Intravitreal market revenue estimates and forecasts, 2018 - 2030 (USD Million)
      • 6.5.1.3. Retrobulbar
        • 6.5.1.3.1. Retrobulbar market revenue estimates and forecasts, 2018 - 2030 (USD Million)
      • 6.5.1.4. Intracameral
        • 6.5.1.4.1. Intracameral market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.6. Sytemic
    • 6.6.1. Sytemic market revenue estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 7. Ophthalmic Drugs Market: Dosage Type Estimates & Trend Analysis

  • 7.1. Segment Dashboard
  • 7.2. Ophthalmic Drugs Market: Dosage Type Movement Analysis
  • 7.3. Ophthalmic Drugs Market Size & Trend Analysis, by Dosage Type, 2018 to 2030 (USD Million)
  • 7.4. Gels
    • 7.4.1. Gels market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • 7.5. Eye solutions & suspensions
    • 7.5.1. Eye solutions & suspensions market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • 7.6. Capsules & Tablets
    • 7.6.1. Capsules & tablets market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • 7.7. Eye drops
    • 7.7.1. Eye drops market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • 7.8. Ointments
    • 7.8.1. Ointments market revenue estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 8. Ophthalmic Drugs Market: Product Type Estimates & Trend Analysis

  • 8.1. Segment Dashboard
  • 8.2. Ophthalmic Drugs Market: Product Type Movement Analysis
  • 8.3. Ophthalmic Drugs Market Size & Trend Analysis, by Product Type, 2018 to 2030 (USD Million)
  • 8.4. OTC
    • 8.4.1. OTC market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • 8.5. Prescription Drugs
    • 8.5.1. Prescription drugs market revenue estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 9. Ophthalmic Drugs Market: Drug Type Estimates & Trend Analysis

  • 9.1. Segment Dashboard
  • 9.2. Ophthalmic Drugs Market: Drug Type Movement Analysis
  • 9.3. Ophthalmic Drugs Market Size & Trend Analysis, by Drug Type, 2018 to 2030 (USD Million)
  • 9.4. Branded Drugs
    • 9.4.1. Branded drugs market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • 9.5. Generic Drugs
    • 9.5.1. Generic drugs market revenue estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 10. Ophthalmic Drugs Market: Regional Estimates & Trend Analysis

  • 10.1. Regional Market Share Analysis, 2023 & 2030
  • 10.2. Regional Market Dashboard
  • 10.3. Global Regional Market Snapshot
  • 10.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 10.5. North America
    • 10.5.1. U.S.
      • 10.5.1.1. Key country dynamics
      • 10.5.1.2. Regulatory framework/Reimbursement
      • 10.5.1.3. Competitive scenario
      • 10.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 10.5.2. Canada
      • 10.5.2.1. Key country dynamics
      • 10.5.2.2. Regulatory framework/Reimbursement
      • 10.5.2.3. Competitive scenario
      • 10.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 10.5.3. Mexico
      • 10.5.3.1. Key country dynamics
      • 10.5.3.2. Regulatory framework/Reimbursement
      • 10.5.3.3. Competitive scenario
      • 10.5.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 10.6. Europe
    • 10.6.1. UK
      • 10.6.1.1. Key country dynamics
      • 10.6.1.2. Regulatory framework/Reimbursement
      • 10.6.1.3. Competitive scenario
      • 10.6.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 10.6.2. Germany
      • 10.6.2.1. Key country dynamics
      • 10.6.2.2. Regulatory framework/Reimbursement
      • 10.6.2.3. Competitive scenario
      • 10.6.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 10.6.3. France
      • 10.6.3.1. Key country dynamics
      • 10.6.3.2. Regulatory framework/Reimbursement
      • 10.6.3.3. Competitive scenario
      • 10.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 10.6.4. Italy
      • 10.6.4.1. Key country dynamics
      • 10.6.4.2. Regulatory framework/Reimbursement
      • 10.6.4.3. Competitive scenario
      • 10.6.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 10.6.5. Spain
      • 10.6.5.1. Key country dynamics
      • 10.6.5.2. Regulatory framework/Reimbursement
      • 10.6.5.3. Competitive scenario
      • 10.6.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 10.6.6. Norway
      • 10.6.6.1. Key country dynamics
      • 10.6.6.2. Regulatory framework/Reimbursement
      • 10.6.6.3. Competitive scenario
      • 10.6.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 10.6.7. Sweden
      • 10.6.7.1. Key country dynamics
      • 10.6.7.2. Regulatory framework/Reimbursement
      • 10.6.7.3. Competitive scenario
      • 10.6.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 10.6.8. Denmark
      • 10.6.8.1. Key country dynamics
      • 10.6.8.2. Regulatory framework/Reimbursement
      • 10.6.8.3. Competitive scenario
      • 10.6.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 10.7. Asia Pacific
    • 10.7.1. Japan
      • 10.7.1.1. Key country dynamics
      • 10.7.1.2. Regulatory framework/Reimbursement
      • 10.7.1.3. Competitive scenario
      • 10.7.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 10.7.2. China
      • 10.7.2.1. Key country dynamics
      • 10.7.2.2. Regulatory framework/Reimbursement
      • 10.7.2.3. Competitive scenario
      • 10.7.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 10.7.3. India
      • 10.7.3.1. Key country dynamics
      • 10.7.3.2. Regulatory framework/Reimbursement
      • 10.7.3.3. Competitive scenario
      • 10.7.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 10.7.4. Australia
      • 10.7.4.1. Key country dynamics
      • 10.7.4.2. Regulatory framework/Reimbursement
      • 10.7.4.3. Competitive scenario
      • 10.7.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 10.7.5. South Korea
      • 10.7.5.1. Key country dynamics
      • 10.7.5.2. Regulatory framework/Reimbursement
      • 10.7.5.3. Competitive scenario
      • 10.7.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 10.7.6. Thailand
      • 10.7.6.1. Key country dynamics
      • 10.7.6.2. Regulatory framework/Reimbursement
      • 10.7.6.3. Competitive scenario
      • 10.7.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 10.8. Latin America
    • 10.8.1. Brazil
      • 10.8.1.1. Key country dynamics
      • 10.8.1.2. Regulatory framework/Reimbursement
      • 10.8.1.3. Competitive scenario
      • 10.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 10.8.2. Argentina
      • 10.8.2.1. Key country dynamics
      • 10.8.2.2. Regulatory framework/Reimbursement
      • 10.8.2.3. Competitive scenario
      • 10.8.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 10.9. MEA
    • 10.9.1. South Africa
      • 10.9.1.1. Key country dynamics
      • 10.9.1.2. Regulatory framework/Reimbursement
      • 10.9.1.3. Competitive scenario
      • 10.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 10.9.2. Saudi Arabia
      • 10.9.2.1. Key country dynamics
      • 10.9.2.2. Regulatory framework/Reimbursement
      • 10.9.2.3. Competitive scenario
      • 10.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 10.9.3. UAE
      • 10.9.3.1. Key country dynamics
      • 10.9.3.2. Regulatory framework/Reimbursement
      • 10.9.3.3. Competitive scenario
      • 10.9.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 10.9.4. Kuwait
      • 10.9.4.1. Key country dynamics
      • 10.9.4.2. Regulatory framework
      • 10.9.4.3. Competitive scenario
      • 10.9.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 11. Competitive Landscape

  • 11.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 11.2. Company/Competition Categorization
  • 11.3. Vendor Landscape
    • 11.3.1. List of key distributors and channel partners
    • 11.3.2. Key customers
    • 11.3.3. Key company market share analysis, 2023
    • 11.3.4. Alcon
      • 11.3.4.1. Company overview
      • 11.3.4.2. Financial performance
      • 11.3.4.3. Services benchmarking
      • 11.3.4.4. Strategic initiatives
    • 11.3.5. Novartis AG
      • 11.3.5.1. Company overview
      • 11.3.5.2. Financial performance
      • 11.3.5.3. Services benchmarking
      • 11.3.5.4. Strategic initiatives
    • 11.3.6. Bausch Health Companies, Inc.
      • 11.3.6.1. Company overview
      • 11.3.6.2. Financial performance
      • 11.3.6.3. Services benchmarking
      • 11.3.6.4. Strategic initiatives
    • 11.3.7. Merck & Co., Inc.
      • 11.3.7.1. Company overview
      • 11.3.7.2. Financial performance
      • 11.3.7.3. Services benchmarking
      • 11.3.7.4. Strategic initiatives
    • 11.3.8. Regeneron Pharmaceuticals, Inc.
      • 11.3.8.1. Company overview
      • 11.3.8.2. Financial performance
      • 11.3.8.3. Services benchmarking
      • 11.3.8.4. Strategic initiatives
    • 11.3.9. Coherus BioSciences, Inc.
      • 11.3.9.1. Company overview
      • 11.3.9.2. Financial performance
      • 11.3.9.3. Services benchmarking
      • 11.3.9.4. Strategic initiatives
    • 11.3.10. AbbVie, Inc. (Allergan)
      • 11.3.10.1. Company overview
      • 11.3.10.2. Financial performance
      • 11.3.10.3. Services benchmarking
      • 11.3.10.4. Strategic initiatives
    • 11.3.11. Pfizer, Inc.
      • 11.3.11.1. Company overview
      • 11.3.11.2. Financial performance
      • 11.3.11.3. Services benchmarking
      • 11.3.11.4. Strategic initiatives
    • 11.3.12. Bayer AG
      • 11.3.12.1. Company overview
      • 11.3.12.2. Financial performance
      • 11.3.12.3. Services benchmarking
      • 11.3.12.4. Strategic initiatives
    • 11.3.13. Santen Pharmaceutical Co., Ltd.
      • 11.3.13.1. Company overview
      • 11.3.13.2. Financial performance
      • 11.3.13.3. Services benchmarking
      • 11.3.13.4. Strategic initiatives
    • 11.3.14. Roche (Genentech, Inc.)
      • 11.3.14.1. Company overview
      • 11.3.14.2. Financial performance
      • 11.3.14.3. Services benchmarking
      • 11.3.14.4. Strategic initiatives
    • 11.3.15. Nicox
      • 11.3.15.1. Company overview
      • 11.3.15.2. Financial performance
      • 11.3.15.3. Services benchmarking
      • 11.3.15.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviations
  • Table 2 North America ophthalmic drugs market, by region, 2018 - 2030 (USD Million)
  • Table 3 North America ophthalmic drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 4 North America ophthalmic drugs market, by disease, 2018 - 2030 (USD Million)
  • Table 5 North America ophthalmic drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 6 North America ophthalmic drugs market, by dosage type, 2018 - 2030 (USD Million)
  • Table 7 North America ophthalmic drugs market, by product type, 2018 - 2030 (USD Million)
  • Table 8 North America ophthalmic drugs market, by drug type, 2018 - 2030 (USD Million)
  • Table 9 U.S. ophthalmic drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 10 U.S. ophthalmic drugs market, by disease, 2018 - 2030 (USD Million)
  • Table 11 U.S. ophthalmic drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 12 U.S. ophthalmic drugs market, by dosage type, 2018 - 2030 (USD Million)
  • Table 13 U.S. ophthalmic drugs market, by product type, 2018 - 2030 (USD Million)
  • Table 14 U.S. ophthalmic drugs market, by drug type, 2018 - 2030 (USD Million)
  • Table 15 Canada ophthalmic drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 16 Canada ophthalmic drugs market, by disease, 2018 - 2030 (USD Million)
  • Table 17 Canada ophthalmic drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 18 Canada ophthalmic drugs market, by dosage type, 2018 - 2030 (USD Million)
  • Table 19 Canada ophthalmic drugs market, by product type, 2018 - 2030 (USD Million)
  • Table 20 Canada ophthalmic drugs market, by drug type, 2018 - 2030 (USD Million)
  • Table 21 Mexico ophthalmic drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 22 Mexico ophthalmic drugs market, by disease, 2018 - 2030 (USD Million)
  • Table 23 Mexico ophthalmic drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 24 Mexico ophthalmic drugs market, by dosage type, 2018 - 2030 (USD Million)
  • Table 25 Mexico ophthalmic drugs market, by product type, 2018 - 2030 (USD Million)
  • Table 26 Mexico ophthalmic drugs market, by drug type, 2018 - 2030 (USD Million)
  • Table 27 Europe ophthalmic drugs market, by region, 2018 - 2030 (USD Million)
  • Table 28 Europe ophthalmic drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 29 Europe ophthalmic drugs market, by disease, 2018 - 2030 (USD Million)
  • Table 30 Europe ophthalmic drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 31 Europe ophthalmic drugs market, by dosage type, 2018 - 2030 (USD Million)
  • Table 32 Europe ophthalmic drugs market, by product type, 2018 - 2030 (USD Million)
  • Table 33 Europe ophthalmic drugs market, by drug type, 2018 - 2030 (USD Million)
  • Table 34 UK ophthalmic drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 35 UK ophthalmic drugs market, by disease, 2018 - 2030 (USD Million)
  • Table 36 UK ophthalmic drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 37 UK ophthalmic drugs market, by dosage type, 2018 - 2030 (USD Million)
  • Table 38 UK ophthalmic drugs market, by product type, 2018 - 2030 (USD Million)
  • Table 39 UK ophthalmic drugs market, by drug type, 2018 - 2030 (USD Million)
  • Table 40 Germany ophthalmic drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 41 Germany ophthalmic drugs market, by disease, 2018 - 2030 (USD Million)
  • Table 42 Germany ophthalmic drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 43 Germany ophthalmic drugs market, by dosage type, 2018 - 2030 (USD Million)
  • Table 44 Germany ophthalmic drugs market, by product type, 2018 - 2030 (USD Million)
  • Table 45 Germany ophthalmic drugs market, by drug type, 2018 - 2030 (USD Million)
  • Table 46 France ophthalmic drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 47 France ophthalmic drugs market, by disease, 2018 - 2030 (USD Million)
  • Table 48 France ophthalmic drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 49 France ophthalmic drugs market, by dosage type, 2018 - 2030 (USD Million)
  • Table 50 France ophthalmic drugs market, by product type, 2018 - 2030 (USD Million)
  • Table 51 France ophthalmic drugs market, by drug type, 2018 - 2030 (USD Million)
  • Table 52 Italy ophthalmic drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 53 Italy ophthalmic drugs market, by disease, 2018 - 2030 (USD Million)
  • Table 54 Italy ophthalmic drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 55 Italy ophthalmic drugs market, by dosage type, 2018 - 2030 (USD Million)
  • Table 56 Italy ophthalmic drugs market, by product type, 2018 - 2030 (USD Million)
  • Table 57 Italy ophthalmic drugs market, by drug type, 2018 - 2030 (USD Million)
  • Table 58 Spain ophthalmic drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 59 Spain ophthalmic drugs market, by disease, 2018 - 2030 (USD Million)
  • Table 60 Spain ophthalmic drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 61 Spain ophthalmic drugs market, by dosage type, 2018 - 2030 (USD Million)
  • Table 62 Spain ophthalmic drugs market, by product type, 2018 - 2030 (USD Million)
  • Table 63 Spain ophthalmic drugs market, by drug type, 2018 - 2030 (USD Million)
  • Table 64 Denmark ophthalmic drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 65 Denmark ophthalmic drugs market, by disease, 2018 - 2030 (USD Million)
  • Table 66 Denmark ophthalmic drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 67 Denmark ophthalmic drugs market, by dosage type, 2018 - 2030 (USD Million)
  • Table 68 Denmark ophthalmic drugs market, by product type, 2018 - 2030 (USD Million)
  • Table 69 Denmark ophthalmic drugs market, by drug type, 2018 - 2030 (USD Million)
  • Table 70 Sweden ophthalmic drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 71 Sweden ophthalmic drugs market, by disease, 2018 - 2030 (USD Million)
  • Table 72 Sweden ophthalmic drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 73 Sweden ophthalmic drugs market, by dosage type, 2018 - 2030 (USD Million)
  • Table 74 Sweden ophthalmic drugs market, by product type, 2018 - 2030 (USD Million)
  • Table 75 Sweden ophthalmic drugs market, by drug type, 2018 - 2030 (USD Million)
  • Table 76 Norway ophthalmic drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 77 Norway ophthalmic drugs market, by disease, 2018 - 2030 (USD Million)
  • Table 78 Norway ophthalmic drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 79 Norway ophthalmic drugs market, by dosage type, 2018 - 2030 (USD Million)
  • Table 80 Norway ophthalmic drugs market, by product type, 2018 - 2030 (USD Million)
  • Table 81 Norway ophthalmic drugs market, by drug type, 2018 - 2030 (USD Million)
  • Table 82 Asia Pacific ophthalmic drugs market, by region, 2018 - 2030 (USD Million)
  • Table 83 Asia Pacific ophthalmic drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 84 Asia Pacific ophthalmic drugs market, by disease, 2018 - 2030 (USD Million)
  • Table 85 Asia Pacific ophthalmic drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 86 Asia Pacific ophthalmic drugs market, by dosage type, 2018 - 2030 (USD Million)
  • Table 87 Asia Pacific ophthalmic drugs market, by product type, 2018 - 2030 (USD Million)
  • Table 88 China ophthalmic drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 89 China ophthalmic drugs market, by disease, 2018 - 2030 (USD Million)
  • Table 90 China ophthalmic drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 91 China ophthalmic drugs market, by dosage type, 2018 - 2030 (USD Million)
  • Table 92 China ophthalmic drugs market, by product type, 2018 - 2030 (USD Million)
  • Table 93 China ophthalmic drugs market, by drug type, 2018 - 2030 (USD Million)
  • Table 94 Japan ophthalmic drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 95 Japan ophthalmic drugs market, by disease, 2018 - 2030 (USD Million)
  • Table 96 Japan ophthalmic drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 97 Japan ophthalmic drugs market, by dosage type, 2018 - 2030 (USD Million)
  • Table 98 Japan ophthalmic drugs market, by product type, 2018 - 2030 (USD Million)
  • Table 99 Japan ophthalmic drugs market, by drug type, 2018 - 2030 (USD Million)
  • Table 100 India ophthalmic drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 101 India ophthalmic drugs market, by disease, 2018 - 2030 (USD Million)
  • Table 102 India ophthalmic drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 103 India ophthalmic drugs market, by dosage type, 2018 - 2030 (USD Million)
  • Table 104 India ophthalmic drugs market, by product type, 2018 - 2030 (USD Million)
  • Table 105 India ophthalmic drugs market, by drug type, 2018 - 2030 (USD Million)
  • Table 106 Australia ophthalmic drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 107 Australia ophthalmic drugs market, by disease, 2018 - 2030 (USD Million)
  • Table 108 Australia ophthalmic drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 109 Australia ophthalmic drugs market, by dosage type, 2018 - 2030 (USD Million)
  • Table 110 Australia ophthalmic drugs market, by product type, 2018 - 2030 (USD Million)
  • Table 111 Australia ophthalmic drugs market, by drug type, 2018 - 2030 (USD Million)
  • Table 112 South Korea ophthalmic drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 113 South Korea ophthalmic drugs market, by disease, 2018 - 2030 (USD Million)
  • Table 114 South Korea ophthalmic drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 115 South Korea ophthalmic drugs market, by dosage type, 2018 - 2030 (USD Million)
  • Table 116 South Korea ophthalmic drugs market, by product type, 2018 - 2030 (USD Million)
  • Table 117 South Korea ophthalmic drugs market, by drug type, 2018 - 2030 (USD Million)
  • Table 118 Thailand ophthalmic drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 119 Thailand ophthalmic drugs market, by disease, 2018 - 2030 (USD Million)
  • Table 120 Thailand ophthalmic drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 121 Thailand ophthalmic drugs market, by dosage type, 2018 - 2030 (USD Million)
  • Table 122 Thailand ophthalmic drugs market, by product type, 2018 - 2030 (USD Million)
  • Table 123 Thailand ophthalmic drugs market, by drug type, 2018 - 2030 (USD Million)
  • Table 124 Latin America ophthalmic drugs market, by region, 2018 - 2030 (USD Million)
  • Table 125 Latin America ophthalmic drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 126 Latin America ophthalmic drugs market, by disease, 2018 - 2030 (USD Million)
  • Table 127 Latin America ophthalmic drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 128 Latin America ophthalmic drugs market, by dosage type, 2018 - 2030 (USD Million)
  • Table 129 Latin America ophthalmic drugs market, by product type, 2018 - 2030 (USD Million)
  • Table 130 Latin America ophthalmic drugs market, by drug type, 2018 - 2030 (USD Million)
  • Table 131 Brazil ophthalmic drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 132 Brazil ophthalmic drugs market, by disease, 2018 - 2030 (USD Million)
  • Table 133 Brazil ophthalmic drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 134 Brazil ophthalmic drugs market, by dosage type, 2018 - 2030 (USD Million)
  • Table 135 Brazil ophthalmic drugs market, by product type, 2018 - 2030 (USD Million)
  • Table 136 Brazil ophthalmic drugs market, by drug type, 2018 - 2030 (USD Million)
  • Table 137 Argentina ophthalmic drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 138 Argentina ophthalmic drugs market, by disease, 2018 - 2030 (USD Million)
  • Table 139 Argentina ophthalmic drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 140 Argentina ophthalmic drugs market, by dosage type, 2018 - 2030 (USD Million)
  • Table 141 Argentina ophthalmic drugs market, by product type, 2018 - 2030 (USD Million)
  • Table 142 Argentina ophthalmic drugs market, by drug type, 2018 - 2030 (USD Million)
  • Table 143 MEA ophthalmic drugs market, by region, 2018 - 2030 (USD Million)
  • Table 144 MEA ophthalmic drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 145 MEA ophthalmic drugs market, by disease, 2018 - 2030 (USD Million)
  • Table 146 MEA ophthalmic drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 147 MEA ophthalmic drugs market, by dosage type, 2018 - 2030 (USD Million)
  • Table 148 MEA ophthalmic drugs market, by product type, 2018 - 2030 (USD Million)
  • Table 149 MEA ophthalmic drugs market, by drug type, 2018 - 2030 (USD Million)
  • Table 150 South Africa ophthalmic drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 151 South Africa ophthalmic drugs market, by disease, 2018 - 2030 (USD Million)
  • Table 152 South Africa ophthalmic drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 153 South Africa ophthalmic drugs market, by dosage type, 2018 - 2030 (USD Million)
  • Table 154 South Africa ophthalmic drugs market, by product type, 2018 - 2030 (USD Million)
  • Table 155 South Africa ophthalmic drugs market, by drug type, 2018 - 2030 (USD Million)
  • Table 156 Saudi Arabia ophthalmic drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 157 Saudi Arabia ophthalmic drugs market, by disease, 2018 - 2030 (USD Million)
  • Table 158 Saudi Arabia ophthalmic drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 159 Saudi Arabia ophthalmic drugs market, by dosage type, 2018 - 2030 (USD Million)
  • Table 160 Saudi Arabia ophthalmic drugs market, by product type, 2018 - 2030 (USD Million)
  • Table 161 Saudi Arabia ophthalmic drugs market, by drug type, 2018 - 2030 (USD Million)
  • Table 162 UAE ophthalmic drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 163 UAE ophthalmic drugs market, by disease, 2018 - 2030 (USD Million)
  • Table 164 UAE ophthalmic drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 165 UAE ophthalmic drugs market, by dosage type, 2018 - 2030 (USD Million)
  • Table 166 UAE ophthalmic drugs market, by product type, 2018 - 2030 (USD Million)
  • Table 167 UAE ophthalmic drugs market, by drug type, 2018 - 2030 (USD Million)
  • Table 168 Kuwait ophthalmic drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 169 Kuwait ophthalmic drugs market, by disease, 2018 - 2030 (USD Million)
  • Table 170 Kuwait ophthalmic drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 171 Kuwait ophthalmic drugs market, by dosage type, 2018 - 2030 (USD Million)
  • Table 172 Kuwait ophthalmic drugs market, by product type, 2018 - 2030 (USD Million)
  • Table 173 Kuwait ophthalmic drugs market, by drug type, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Primary interviews in Europe
  • Fig. 6 Primary interviews in APAC
  • Fig. 7 Primary interviews in Latin America
  • Fig. 8 Primary interviews in MEA
  • Fig. 9 Market research approaches
  • Fig. 10 Value-chain-based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 Ophthalmic drugs market: market outlook
  • Fig. 14 Ophthalmic drugs competitive insights
  • Fig. 15 Parent market outlook
  • Fig. 16 Related/ancillary market outlook
  • Fig. 17 Penetration and growth prospect mapping
  • Fig. 18 Industry value chain analysis
  • Fig. 19 Ophthalmic drugs market driver impact
  • Fig. 20 Ophthalmic drugs market restraint impact
  • Fig. 21 Ophthalmic drugs market strategic initiatives analysis
  • Fig. 22 Ophthalmic drugs market: Drug class movement analysis
  • Fig. 23 Ophthalmic drugs market: Drug class outlook and key takeaways
  • Fig. 24 Anti-Allergy market estimates and forecasts, 2018 - 2030
  • Fig. 25 Anti-VEGF agents market estimates and forecasts, 2018 - 2030
  • Fig. 26 Anti-inflammatory market estimates and forecasts, 2018 - 2030
  • Fig. 27 Non steroidal drugs market estimates and forecasts, 2018 - 2030
  • Fig. 28 Steroidal drugs market estimates and forecasts, 2018 - 2030
  • Fig. 29 Anti glaucoma market estimates and forecasts, 2018 - 2030
  • Fig. 30 Gene & cell therapy market estimates and forecasts, 2018 - 2030
  • Fig. 31 Others market estimates and forecasts, 2018 - 2030
  • Fig. 32 Ophthalmic drugs market: Disease movement analysis
  • Fig. 33 Ophthalmic drugs market: Disease outlook and key takeaways
  • Fig. 34 Dry eye market estimates and forecasts, 2018 - 2030
  • Fig. 35 Gels market estimates and forecasts, 2018 - 2030
  • Fig. 36 Eye solutions & suspensions market estimates and forecasts, 2018 - 2030
  • Fig. 37 Capsules & tablets market estimates and forecasts, 2018 - 2030
  • Fig. 38 Eye drops market estimates and forecasts, 2018 - 2030
  • Fig. 39 Ointments market estimates and forecasts, 2018 - 2030
  • Fig. 40 Allergies market estimates and forecasts, 2018 - 2030
  • Fig. 41 Gels market estimates and forecasts, 2018 - 2030
  • Fig. 42 Eye solutions & suspensions market estimates and forecasts, 2018 - 2030
  • Fig. 43 Capsules & tablets market estimates and forecasts, 2018 - 2030
  • Fig. 44 Eye drops market estimates and forecasts, 2018 - 2030
  • Fig. 45 Ointments market estimates and forecasts, 2018 - 2030
  • Fig. 46 Glaucoma market estimates and forecasts, 2018 - 2030
  • Fig. 47 Gels market estimates and forecasts, 2018 - 2030
  • Fig. 48 Eye solutions & suspensions market estimates and forecasts, 2018 - 2030
  • Fig. 49 Capsules & tablets market estimates and forecasts, 2018 - 2030
  • Fig. 50 Eye drops market estimates and forecasts, 2018 - 2030
  • Fig. 51 Ointments market estimates and forecasts, 2018 - 2030
  • Fig. 52 Infection market estimates and forecasts, 2018 - 2030
  • Fig. 53 Gels market estimates and forecasts, 2018 - 2030
  • Fig. 54 Eye solutions & suspensions market estimates and forecasts, 2018 - 2030
  • Fig. 55 Capsules & tablets market estimates and forecasts, 2018 - 2030
  • Fig. 56 Eye drops market estimates and forecasts, 2018 - 2030
  • Fig. 57 Ointments market estimates and forecasts, 2018 - 2030
  • Fig. 58 Retinal disorders market estimates and forecasts, 2018 - 2030
  • Fig. 59 By type market estimates and forecasts, 2018 - 2030
  • Fig. 60 Macular degeneration market estimates and forecasts, 2018 - 2030
  • Fig. 61 Diabetic retinopathy market estimates and forecasts, 2018 - 2030
  • Fig. 62 Others market estimates and forecasts, 2018 - 2030
  • Fig. 63 By dosage type market estimates and forecasts, 2018 - 2030
  • Fig. 64 Gels market estimates and forecasts, 2018 - 2030
  • Fig. 65 Eye solutions & suspensions market estimates and forecasts, 2018 - 2030
  • Fig. 66 Capsules & tablets market estimates and forecasts, 2018 - 2030
  • Fig. 67 Eye drops market estimates and forecasts, 2018 - 2030
  • Fig. 68 Ointments market estimates and forecasts, 2018 - 2030
  • Fig. 69 Uveitis market estimates and forecasts, 2018 - 2030
  • Fig. 70 Gels market estimates and forecasts, 2018 - 2030
  • Fig. 71 Eye solutions & suspensions market estimates and forecasts, 2018 - 2030
  • Fig. 72 Capsules & tablets market estimates and forecasts, 2018 - 2030
  • Fig. 73 Eye drops market estimates and forecasts, 2018 - 2030
  • Fig. 74 Ointments market estimates and forecasts, 2018 - 2030
  • Fig. 75 Others market estimates and forecasts, 2018 - 2030
  • Fig. 76 Gels market estimates and forecasts, 2018 - 2030
  • Fig. 77 Eye solutions & suspensions market estimates and forecasts, 2018 - 2030
  • Fig. 78 Capsules & tablets market estimates and forecasts, 2018 - 2030
  • Fig. 79 Eye drops market estimates and forecasts, 2018 - 2030
  • Fig. 80 Ointments market estimates and forecasts, 2018 - 2030
  • Fig. 81 Ophthalmic drugs market: Dosage type movement analysis
  • Fig. 82 Ophthalmic drugs market: Dosage type outlook and key takeaways
  • Fig. 83 Gels market estimates and forecasts, 2018 - 2030
  • Fig. 84 Eye solutions & suspensions market estimates and forecasts, 2018 - 2030
  • Fig. 85 Capsules & tablets market estimates and forecasts, 2018 - 2030
  • Fig. 86 Eye drops market estimates and forecasts, 2018 - 2030
  • Fig. 87 Ointments market estimates and forecasts, 2018 - 2030
  • Fig. 88 Ophthalmic drugs market: Route of administration movement analysis
  • Fig. 89 Ophthalmic drugs market: Route of administration outlook and key takeaways
  • Fig. 90 Topical market estimates and forecasts, 2018 - 2030
  • Fig. 91 Local Ocular market estimates and forecasts, 2018 - 2030
  • Fig. 92 Subconjunctival market estimates and forecasts, 2018 - 2030
  • Fig. 93 Intravitreal market estimates and forecasts, 2018 - 2030
  • Fig. 94 Retrobulbar market estimates and forecasts, 2018 - 2030
  • Fig. 95 Intracameral market estimates and forecasts, 2018 - 2030
  • Fig. 96 Sytemic market estimates and forecasts, 2018 - 2030
  • Fig. 97 Ophthalmic drugs market: Product type movement analysis
  • Fig. 98 Ophthalmic drugs market: Product type outlook and key takeaways
  • Fig. 99 OTC market estimates and forecasts, 2018 - 2030
  • Fig. 100 Prescription drugs market estimates and forecasts, 2018 - 2030
  • Fig. 101 Ophthalmic drugs market: Drug type movement analysis
  • Fig. 102 Ophthalmic drugs market: Drug type outlook and key takeaways
  • Fig. 103 Branded drugs market estimates and forecasts, 2018 - 2030
  • Fig. 104 Generic drugs market estimates and forecasts, 2018 - 2030
  • Fig. 105 Global ophthalmic drugs market: Regional movement analysis
  • Fig. 106 Global ophthalmic drugs market: Regional outlook and key takeaways
  • Fig. 107 Global ophthalmic drugs market share and leading players
  • Fig. 108 North America market share and leading players
  • Fig. 109 Europe market share and leading players
  • Fig. 110 Asia Pacific market share and leading players
  • Fig. 111 Latin America market share and leading players
  • Fig. 112 Middle East & Africa market share and leading players
  • Fig. 113 North America, by country
  • Fig. 114 North America
  • Fig. 115 North America market estimates and forecasts, 2018 - 2030
  • Fig. 116 U.S. key country dynamics
  • Fig. 117 U.S. market estimates and forecasts, 2018 - 2030
  • Fig. 118 Canada country dynamics
  • Fig. 119 Canada market estimates and forecasts, 2018 - 2030
  • Fig. 120 Mexico country dynamics
  • Fig. 121 Mexico market estimates and forecasts, 2018 - 2030
  • Fig. 122 Europe
  • Fig. 123 Europe market estimates and forecasts, 2018 - 2030
  • Fig. 124 UK country dynamics
  • Fig. 125 UK market estimates and forecasts, 2018 - 2030
  • Fig. 126 Germany
  • Fig. 127 Germany market estimates and forecasts, 2018 - 2030
  • Fig. 128 France country dynamics
  • Fig. 129 France market estimates and forecasts, 2018 - 2030
  • Fig. 130 Italy country dynamics
  • Fig. 131 Italy market estimates and forecasts, 2018 - 2030
  • Fig. 132 Spain country dynamics
  • Fig. 133 Spain market estimates and forecasts, 2018 - 2030
  • Fig. 134 Denmark country dynamics
  • Fig. 135 Denmark market estimates and forecasts, 2018 - 2030
  • Fig. 136 Sweden country dynamics
  • Fig. 137 Sweden market estimates and forecasts, 2018 - 2030
  • Fig. 138 Norway country dynamics
  • Fig. 139 Norway market estimates and forecasts, 2018 - 2030
  • Fig. 140 Asia Pacific
  • Fig. 141 Asia Pacific market estimates and forecasts, 2018 - 2030
  • Fig. 142 China country dynamics
  • Fig. 143 China market estimates and forecasts, 2018 - 2030
  • Fig. 144 Japan country dynamics
  • Fig. 145 Japan market estimates and forecasts, 2018 - 2030
  • Fig. 146 India country dynamics
  • Fig. 147 India market estimates and forecasts, 2018 - 2030
  • Fig. 148 Thailand country dynamics
  • Fig. 149 Thailand market estimates and forecasts, 2018 - 2030
  • Fig. 150 South Korea country dynamics
  • Fig. 151 South Korea market estimates and forecasts, 2018 - 2030
  • Fig. 152 Australia country dynamics
  • Fig. 153 Australia market estimates and forecasts, 2018 - 2030
  • Fig. 154 Latin America
  • Fig. 155 Latin America market estimates and forecasts, 2018 - 2030
  • Fig. 156 Brazil country dynamics
  • Fig. 157 Brazil market estimates and forecasts, 2018 - 2030
  • Fig. 158 Argentina country dynamics
  • Fig. 159 Argentina market estimates and forecasts, 2018 - 2030
  • Fig. 160 Middle East and Africa
  • Fig. 161 Middle East and Africa market estimates and forecasts, 2018 - 2030
  • Fig. 162 South Africa country dynamics
  • Fig. 163 South Africa market estimates and forecasts, 2018 - 2030
  • Fig. 164 Saudi Arabia country dynamics
  • Fig. 165 Saudi Arabia market estimates and forecasts, 2018 - 2030
  • Fig. 166 UAE country dynamics
  • Fig. 167 UAE market estimates and forecasts, 2018 - 2030
  • Fig. 168 Kuwait country dynamics
  • Fig. 169 Kuwait market estimates and forecasts, 2018 - 2030
  • Fig. 170 Market share of key market players - Syndromic multiplex diagnostics market, 2023
  • Fig. 171 Company Categorization